glp-1 and parkinson's disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular and neurodegenerative disorders GLP-1/GIP dual agonist tirzepatide alleviates

October 3 , 2025: Man in Maryland Becomes Blind After Taking Ozempic to Manage His Diabetes Like many others, Todd Engel took the semaglutide Ozempic to help him keep his Type 2 diabetes under control

That creates uncertainty in areas such as: long-term use beyond typical protocol durations rare side effects that require large sample sizes to detect interactions with complex medication regimens outcomes in special populations such as pregnancy, cancer history, or severe autoimmune disease The right response to uncertainty is not fear, and it is not blind confidence

Sales increased more than 500% over that five-year span

Over time, even under ideal conditions, peptide shelf life will reach its limit

There are no published studies showing its efficacy for weight loss in animals or people

September 20, 2022